article
Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives
Bioorganic & Medicinal Chemistry Letters · 1997 · Vol. 7(2) · pp. 187–192
J. Zimmermann✉(Novartis (Switzerland))Elisabeth Buchdunger(Novartis (Switzerland))Helmut Mett(Novartis (Switzerland))Thomas Meyer(Novartis (Switzerland))Nicholas Lydon(Novartis (Switzerland))
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchQuinazolinone synthesis and applicationsChemistryTyrosine kinaseChronic myelogenous leukemiaABLKinaseIC50PotencySelectivityProtein kinase AEnzyme inhibitor
Citations
242
FWCI
1.92
field-weighted impact
References
11
Percentile
86%
vs. same field & year
Citations per year
Cited by
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Journal of Medicinal Chemistry · 2005 · 1,171 citations
Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors
Journal of Pharmacology and Experimental Therapeutics · 2000 · 1,280 citations
References
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Nature Medicine · 1996 · 3,643 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.